A groundbreaking prognostic test developed through collaboration between The University of Western Australia and Perth-based Proteomics International has been highlighted as the most prominent translational outcome in diabetes research by the National Health and Medical Research Council (NHMRC).
In a recent national report evaluating outcomes of NHMRC-funded programs in diabetes from 2000 to 2023, PromarkerD was recognised for its significant advancement in the clinical prediction of diabetic kidney disease.
The revolutionary blood test, which can predict kidney function decline up to four years before clinical symptoms appear, was developed using samples and data from the NHMRC-funded landmark Fremantle Diabetes Study.
Professor Timothy Davis from UWA Medical School, a key researcher behind the innovation, said the acknowledgment from NHMRC validated years of collaborative research between UWA’s Fremantle Hospital Unit and Proteomics International.
